BIIB

$198.18

▼-2.70%

wb_incandescent Backtest

Stock

Biogen Inc. Common Stock

Official Company Name: Biogen Inc.

Stock Symbol: BIIB

Stock Market: NASDAQ Global Select - NASDAQ

Currency: United States dollar - USD

business Biogen Inc. Company Profile

BIIB Stock Price - 1 Year Price Evolution & Moving Averages

1 Year Return

▼-31.59%

file_download

Daily closing prices, with moving averages and volumes - United States dollar (USD)
Moving averages:

  • EMA20
  • SMA50
  • SMA200

Company Description

Biogen Inc. is a biotechnology company specialized in the treatment of neurological diseases. It researches, develops, and markets therapies for a range of diseases including Alzheimer’s disease, hemophilia, multiple sclerosis, spinal muscular atrophy, plaque psoriasis, leukemia, rheumatoid arthritis, lymphoma, neurocognitive disorders, and pain.

business Biogen Inc. Company Profile

BIIB Stock Data

Open $204.23
High $205.24
Low $197.79
Close $198.18
Volume 1,223,199
Previous Close $203.68
1-Day Change -5.50
1-Year Change -91.52
Average Daily Volume 1,077,727
52-Week High $318.06
52-Week Low $198.18

BIIB Stock References

warning

Disclaimer

All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!

Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.

Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).

Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.

Please conduct your own due diligence to verify insights.